Antibody Drug Conjugate Formation Using 2‐ <sup>14</sup> C‐Iminothiolane: A Radiochemical Analysis of Sequential Lysine Conjugation, Uncloaking of a Phantom Drug‐to‐Antibody Ratio, and Stability of the ADC
[<sup>14</sup>C]2-Iminothiolane ([<sup>14</sup>C]2-IT) served as a highly informative analytical tool to determine the rate of lysine thiolation and total addition of 2-IT to a monoclonal antibody. Specific activity measurements on [<sup>14</sup>C]2-IT modified mAbs found that lysine thiolation with 2-IT is linear regarding time and dependent on buffer strength. Conjugation with a fluorescent maleimide directly linked the free thiol-to-antibody ratio (FTAR) to the [<sup>14</sup>C]2-IT-to-antibody ratio ([<sup>14</sup>C]ITAR), providing accurate predictive information on the true number of sites proficient for payload conjugation and, by comparison with conjugation with the cytotoxic payload, quantified the absorbance from the nonconjugated cyclized N-substituted 2-iminothiolane adduct that created "phantom" drug-to-antibody ratios (PhDAR). Hydrolytic loss of the nonconjugated cyclized N-substituted 2-iminothiolane adduct was investigated using carbon-14 based radioquantitative HPLC, mass spectral analysis, and orthogonal [<sup>14</sup>C]ITAR and DAR measurements of the isolated [<sup>14</sup>C]mAb. These measurements combined to demonstrate that significant amounts of the cyclized products were shed from the [<sup>14</sup>C]ADC as [<sup>14</sup>C]thiobutyrolactone.
Authors
- Selin Aytar
- Annie Tam
- Difei Qiu
- Sharon Gong
- Alban J. Allentoff (ORCID: https://orcid.org/0000-0001-7195-1936)
- Michael Hay (ORCID: https://orcid.org/0000-0003-3752-0408)
- Michael J. Smith (ORCID: https://orcid.org/0000-0003-1478-8081)
- John A. Brailsford (ORCID: https://orcid.org/0009-0002-7001-913X)
- Michael A. Wallace
- Samuel J. Bonacorsi
Institutions
- Bristol-Myers Squibb (Germany) (DE)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Bristol-Myers Squibb (Sweden) (SE)
Publication Details
- Journal
- Journal of Labelled Compounds and Radiopharmaceuticals
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/jlcr.70002
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00